The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate COVID-19: A personal experience from an attending pharmacist and his resident

Main Article Content

Parisa Ghasemiyeh http://orcid.org/0000-0002-8640-5724
Soliman Mohammadi-Samani http://orcid.org/0000-0002-1007-1422

Keywords

COVID-19, Pharmacotherapy, Anti-inflammatory therapy, Personal experience

Abstract

I am a professor and attending pharmacist in the field of pharmaceutical sciences and writer or co-author of at least 5 manuscripts about different aspects of COVID-19. More than 15 months from the first report of COVID-19, over 120 million people all over the world infected by this virus, and more than 2.5 million of them have died. Although different treatment approaches have been proposed, management of the COVID-19 patients is steal remained controversial. In this regard, I want to share my personal experience from the exposure to the coronavirus and the consequence of this infection on my health status. I am a 51 years old male, known case of hypertension, dyslipidemia, and chronic kidney disease. During working hours of colleagues in the Faculty of Pharmacy, I visited one of my colleagues in his office. After leaving the Faculty, my colleague declares that his RT-PCR test of COVID-19 is positive and it took 3 days for me to experience the first sign of the COVID-19 as fever. Many complications have occurred for me during the different stages of COVID-19 infection that I shared and explained in detail with the suggested pharmacotherapies. According to the pathophysiology of COVID-19 infection and my personal experience during COVID-19 infection, I want to emphasize the necessity of early initiation of anti-inflammatory agents including corticosteroids and colchicine in high-risk patients with mild-to-moderate COVID-19 pneumonia who shows respiratory system involvement, in order to prevent progression to the severe and critical stages of this disease.

Downloads

Download data is not yet available.
Abstract 393 | PDF Downloads 133

References

1. Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, Mohammadi-Samani S, Vazin A, Safari A, et al. Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review. Therapeutics and Clinical Risk Management. 2020;16:595.
2. Ghasemiyeh P, Mohammadi-Samani S. Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19? Trends in Pharmaceutical Sciences. 2020;6(2):65-6.
3. Ghasemiyeh P, Mohammadi-Samani S. COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart & Lung. 2020.
4. Park JJ, Decloedt EH, Rayner CR, Cotton M, Mills EJ. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. The Lancet Global Health. 2020;8(10):e1249-e50.
5. Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. 2020;324(13):1330-41.
6. Deftereos S, Giannopoulos G, Vrachatis DA, Siasos G, Giotaki SG, Cleman M, et al. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? European Heart Journal-Cardiovascular Pharmacotherapy. 2020;6(4):255-.